• Best Cryptos to Buy in December 2024: Qubetics Presale Goes Ballistic as Ethereum and Quant Look to Build Momentum
• USDC and CCTP to launch on Aptos, with Stripe adding Aptos support in crypto products
• Best Cryptos to Buy: Qubetics Set to Rise, Bitcoin Knocks at $100k Milestone, Avalanche to Release 1.67M Tokens
• Ike Goes Live on Mainnet: Unlocking Liquid Staking on Aleph Zero
• Native USDC on Aptos Coming Soon to Boost DeFi and P2P Transactions
• Coinshift Launches csUSDL, Announces Strategic Partnerships
• Strategic Bitcoin Reserve Driven by 5-Year Commitment to Buy BTC
• Next Crypto to Explode in 2025: Top 7 Picks You Should Invest in Now
• Solana Spot ETF Applications Progress as SEC Reviews Forms
• Quai Network Testnet Launches With 10M QUAI Rewards
Vitalik Buterin Charity Donation from MOODENG Token Sale
October 7, 2024 - Around 1 mins mins to read
Key Points:
- Vitalik Buterin sold 10 billion MOODENG tokens for 308.7 ETH, donating 260.15 ETH to the Kanro charity for anti-airborne-disease technology.
- Vitalik supports memecoin charity donations, encouraging communities to donate directly or form DAOs to engage in positive-sum contributions.
Vitalik Buterin sold 10 billion MOODENG tokens for 308.7 ETH, donating 260.15 ETH to Kanro charity, emphasizing Vitalik Buterin Charity Donation for disease research.
Vitalik Buterin Charity Donation Supports Disease Research
Vitalik Buterin sold 10 billion MOODENG tokens for 308.7 ETH and then sent 260.15 ETH to the Kanro charity. The donation will fund anti-airborne-disease technologies. He praised memecoins giving something to charities and asked more communities to engage in charity-focused initiatives.
Read more: MegaETH Review: Layer 2 Invested by Vitalik Buterin
Vitalik Buterin’s Commitment to Charity Through Memecoins
As part of his trend of donating proceeds from his sale of MOODENG tokens, Vitalik Buterin fosters memecoin community maximal positivity-sum; this time, the proceeds go to the development of solutions for airborne diseases.
DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing. |